The Safety And Efficacy Evaluation Of Recombinant Human Collagen Vaginal Gel For The Treatment Of Vaginal Dryness

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007266

Enrollment

Unknown

Registered

2015-10-21

Start date

2014-02-13

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Dryness

Interventions

Test group:Recombinant Human Collagen Vaginal Gel therapy

Control group:Hyaluronic acid derivatives vaginal gel therapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 40-65years old, Female sexual life, who were diagnosed at vaginal dryness, painful intercourse clinical symptoms, and (or) of vaginal atrophy such as vaginal secretions decrease and vaginal mucous membrane elasticity down.

Exclusion criteria

Exclusion criteria: 1. Liver and kidney organic diseases; 2. with past 3-6 months participanted in any hormonal drugs; 3. Pregnancy and nursing mothers; 4. Have other effects on the evaluation of the efficacy of the vagina or vulva disease; 5. Gynecological transvaginal ultrasound prompted the postmenopausal endometrial thickness >5mm, or have the endometrial thickness >15mm; 6. 1 years without cervical cytology or cervical cytology abnormal; 7. Patients who have participated in other clinical trials for three months; 8. Allergic to components of Recombinant Human Collagen Vaginal Gel.

Design outcomes

Primary

Measure	Time frame
Vaginal dryness index;	—

Countries

China

Contacts

Public ContactXia Yang

yang-xia1974@163.com+86 13663512021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026